Rezafungin: First Approval

被引:38
作者
Syed, Yahiya Y. [1 ]
机构
[1] Springer Nat, Mairangi Bay Private Bag 65901, Auckland 0754, New Zealand
关键词
CD101; ECHINOCANDIN;
D O I
10.1007/s40265-023-01891-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rezafungin (Rezzayo (TM)), an intravenous once-weekly echinocandin that inhibits 1,3-beta-d-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged >= 18 years who have limited or no alternative treatment options. Rezafungin is also being developed for the prevention of invasive fungal diseases in blood and marrow transplant recipients. This article summarizes the milestones in the development of rezafungin leading to the first approval for the treatment of candidaemia and invasive candidiasis.
引用
收藏
页码:833 / 840
页数:8
相关论文
共 44 条
[1]  
[Anonymous], 2023, DAT FIL
[2]  
Bader JC, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.02614-17, 10.1128/AAC.02614-17]
[3]   Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata [J].
Carvalhaes, Cecilia G. ;
Rhomberg, Paul R. ;
Pfaller, Michael A. ;
Locke, Jeffrey B. ;
Castanheira, Mariana .
MYCOSES, 2022, 65 (11) :1040-1044
[4]   Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020) [J].
Carvalhaes, Cecilia G. ;
Klauer, Abby L. ;
Rhomberg, Paul R. ;
Pfaller, Michael A. ;
Castanheira, Mariana .
JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (04)
[5]  
Carvalhaes CG., 2022, OPEN FORUM INFECT DI, V9, pofac492.1361, DOI 10.1093/ofid/ofac492.1361
[6]  
Cidara T, 2018, FDA GRANTS QIDP FAST
[7]  
Cidara Therapeutics, 2016, CID REC ORPH DRUG DE
[8]  
Cidara Therapeutics, 2015, FDA GRANTS QIDP FAST
[9]  
Cidara Therapeutics, 2019, CID THER MUND FORM S
[10]  
Cidara Therapeutics, 2023, CID THER MEL THER AN